Atkins, M., Hidalgo, M., Stadler, W.M., Logan, T., Dutcher, J., Hudes, G., Young, P., Song-Heng, L., Marshall, B., Boni, J., Dukart, G. Randomized phase II study of multiple dose levels of CCI-779, a novel mTOR kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. (in press).
Dreicer, R., Manola, J., Roth, B.J., See, W.A., Kuross, S., Edelman, M., Hudes, G.R., Wilding, G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) versus carboplatin and paclitaxel in patients with advanced adenocarcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer (in press).
Hudes, G., Menon, S., Golemis, E.A. Protein Interaction-Targeted Drug Discovery. John Wiley (in press).
Mueller, T.J. Wu, H., Greenberg, R.E., Hudes, G., Topham, N., Lessin, S.R., Uzzo, R.G. Cutaneous metastases from genitourinary malignancies. Urology (in press).
Rogatko, A., Babb, J.S., Wang, H., Slifker, M.J., Hudes, G.R. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin. Cancer Res. (in press).
Cohen, S.J., Ho, L., Ranganathan, S., Abbruzzese, J.L., Alpaugh, K., Beard, M., Lewis, N., McLaughlin, S., Rogatko, A., Ruixo, J.J.P., Thistle, A.M., Verhaeghe, T., Wang, H., Weiner, L.M., Wright, J.J., Hudes, G.R., Meropol, N.J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21(7):1301-1306, 2003.
David, A.K., Khwaja, R., Hudes, G.R. Treatments for improving survival of patients with prostate cancer. Drugs Aging 20(9):683-699, 2003.
Haas, N., Smith, M., Lewis, N., Littman, L., Yeslow, G., Joshi, I.D., Murgo, A., Bradley, J., Gordon, R., Wang, H., Rogatko, A., Hudes, G.R. Weekly bryostatin-1 in metastatic renal cell carcinoma: A Fox Chase Network phase II study. Clin. Cancer Res. 9(1):109-114, 2003.
Haas, N.B., Giantonio, B.J., Litwin, S., Minniti, C., Fox, S., Yeslow, G., Reilly, R., Nahum, K., Greenberg, R., Halbherr, T., Hudes, G.R. Vinblastine and estramustine phosphate in metastatic renal carcinoma: a phase II trial of the Fox Chase Network. Cancer 98:1837-1841, 2003.
Twine, N.C., Stover, J.A., Marshall, B., Dukart, G., Strahs, A., Hidalgo, M., Stadler, W., Logan, T., Dutcher, J., Hudes, G., Dorner, A.J., Slonim, D.K., Trepicchio, W.L., Burczynski, M.E. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 63(18):6029-6075, 2003.
Uzzo, R.G., Cairns, P., Al-Saleem, T., Hudes, G., Haas, N., Greenberg, R.E., Kolenko, V. The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol. Clin. N. Am. 30(3):423-436, 2003.
Hudes, G., Haas, N., Yeslow, G., Gilon T, Gunnarsson, P.O., Ellman, M., Nordle, O., Eriksson, B., Miller, L., Cisar, L., Kopreski, M., Viaro, D., Hartley-Asp, B. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J. Clin. Oncol. 20(4):1115-1127, 2002.
Hudes, G. Signaling inhibitors in prostate cancer. Invest. New Drug 20(2):159-172, 2002.
Hudes, G. Boosting bioavailability of topotecan: What do we gain? J. Clin. Oncol. 20(13):2918-2919, 2002.
Haas, N., Roth, B., Garay, C., Yeslow, G., Entmacher, M., Weinstein, A., Rogatko, A., Babb, J., Minnitti, C., Flinker, D., Gillen, T., Greenberg, R., Hudes, G. Phase I trial of weekly paclitaxel plus daily oral estramustine phosphate in patients with hormone refractory prostate cancer. Urology 58:59-64, 2001.
Obasaju, C., Manola J., Hudes, G.R., Khandekar, J.D., Citrin, D.L., Carbone, P., Trump, D.L. Phase II evaluation of menogaril in advanced prostate cancer: An Eastern Cooperative Oncology Group Study P-A885. Am. J. Clin. Oncol. 24(2):150-154, 2001.
Obasaju, C., Hudes G.R. Paclitaxel and Docetaxel in prostate cancer. Hemat. Oncol. Clin. North Am. 15 (3):525-545, 2001.
Ranganathan, S., McCauley, R.A., Dexter, D.W., Hudes, G.R. Modulation of endogenous ?-tubulin isotype expression as a result of human ?III cDNA transfection into prostate carcinoma cells. Br. J. Cancer 85 (5):735-740, 2001.
Schulsinger, A. Ramesh, V., Rotman, M., Hudes, G. Bladder Cancer: Radiotherapy and Chemotherapy. In Atlas of Genitourinary Oncology, edited by B. Movsas, C. Olsson, G. Hudes. W.B. Saunders, Philadelphia, pp. 95-115, 2001.